| Text: | improvements in DBPC patient-reported consequences from baseline were statistically noteworthy for both sildenafil 50 and 100 mg likened with placebo. By the end of DBPC treatment, 56% of men on the 100-mg dose felt no anxiety about the next intercourse attempt associated with 39% in the 50-mg group (odds ratio 2.03; P = 0.0197). Changes in practical scores from baseline were not statistically noteworthy with the 100-mg dose compared with the 50-mg dose in the DBPC. Measures of action satisfaction and erotic experience knowingly favored the 100-mg dose linked with the 50-mg dose in the DBPC. There was no surge in adverse actions with the sophisticated dose. |